Rare cancer patients still have limited access to personalised care in Europe
Despite advances in molecular profiling, only a small fraction of patients with actionable alterations receive matched targeted therapies or immunotherapies
Can AI chatbots effectively support patients with cancer during treatments?
Early findings suggest potential benefits in symptom monitoring, but highlight usability challenges and added burden on clinical workflows
Optimising cancer care to improve clinical outcomes and sustainability
From chronotherapy to immunotherapy resistance, refining when and for whom treatments work is becoming central to making oncology sustainable
CTLA-4 targeting leads to improved overall survival in NSCLC progressing on immunotherapy
Early phase III trial results signal a much-needed chemotherapy-free advance with gotistobart in a setting where therapeutic choices are limited
Meta-analysis shows non-inferiority of later versus earlier immunotherapy administration in lung cancer
Chrono-immunotherapy may influence treatment outcomes, especially during the early phase of treatment, but its overall clinical impact remains to be clearly defined
Adagrasib shows meaningful benefits in older patients with mutated NSCLC
Data reassures on targeting KRAS G12C mutations in older patients who reflect a large part of the real-world population seen in clinics
Data show how ESMO’s scales and recommendations can guide the optimisation of outcomes in patients with targetable mutations
In two studies, the use of ESCAT matching and ESMO recommendations for germline assessment lead to effective targeted treatment
Data highlight the clinical feasibility of targeting the CD47-SIRPα axis mediating immunotherapy resistance
Early activity and manageable safety were demonstrated in two phase I trials with innovative agents
A driving force to accelerate drug development
Fostering academic clinical research is one of the ESMO’s priorities, and artificial intelligence may be a major driver
Ozekibart added to chemotherapy demonstrates robust activity in relapsed/refractory Ewing sarcoma
Preliminary data on the tetravalent DR5 agonist indicate strong and durable responses with a manageable safety profile